Beaufond Plc Charts European Course: Advanced Negotiations Under Way for Strategic API Supply Alliance with Netherlands Pharmaceutical Group
Beaufond PLC’s bold expansion into the Netherlands signals a new chapter in its global journey. By aligning with Europe’s most advanced pharmaceutical ecosystem, the company is not just chasing revenue growth—it is positioning itself at the heart of innovation in life sciences, where the fight against cancer and malaria demands relentless commitment and global collaboration.Strategic Dutch alliance to accelerate Beaufond PLC’s oncology and anti-malarial API supply chain, driving robust revenue growth across its Pharma & Chemicals verticals.
Dubai-based global API and specialty chemicals distributor Beaufond Plc — which posted audited revenues of USD 3.03 billion in FY2024-25, is a AA investment-grade company, and operates with effectively zero funded debt — is understood to be in advanced discussions for a major oncology and anti-malarial API supply agreement with a leading Netherlands-headquartered pharmaceutical company. The deal, if concluded, would mark a significant step in Beaufond’s structured push into continental Europe ahead of its planned IPO.
| USD 3.03B
FY25 Audited Revenue |
22.7%
5-Year Revenue CAGR |
Company Internally Rated AA
|
50+ Countries
Global Market Reach |
THE DEAL
A Strategic Foothold in Europe’s High-Potency API Heartland
Network 7 Media Group has learned that Beaufond Plc, headquartered in the Dubai International Financial Centre (DIFC) and registered under DIFC Companies Law No. 5 of 2018 (Registration No. 3122), is in advanced negotiations for a long-term supply partnership with a Netherlands-based pharmaceutical manufacturer. The collaboration is centred on the supply of Active Pharmaceutical Ingredients (APIs) and chemical intermediates for oncology and anti-malarial therapeutic segments.
The Netherlands is one of Europe’s most sophisticated pharmaceutical manufacturing environments. Home to major API producers and a well-developed logistics infrastructure, it serves as a critical gateway to pan-European drug distribution. With the global High-Potency API (HPAPI) market projected to grow significantly through 2030 — driven by rising cancer incidence and demand for complex molecule therapies — the timing of Beaufond’s push into this geography is strategically calculated.
Beaufond’s existing regulatory credentials — US FDA, European Medicines Agency (EMA), UK MHRA, Health Canada, TGA Australia, WHO-GMP, and PIC/S compliance — position it as a credible and immediately deployable supply partner for any European pharma manufacturer requiring a reliably compliant API source. The company recorded zero critical observations across all FY2024-25 regulatory inspections, a distinction rare at its scale.
| “Zero critical observations across all FY2024-25 regulatory inspections. Fifteen new Drug Master Files filed with US FDA, EMA, and MHRA in a single year — a regulatory moat few distributors at this scale can match.” |
FINANCIAL FOUNDATION — VERIFIED FROM AUDITED ACCOUNTS
USD 3.03 Billion in Revenue. Zero Funded Debt. USD 897 Million in Equity.
Any assessment of Beaufond’s European ambitions must be anchored in its independently audited financial record. The FY2024-25 Annual Report — audited by Youssry & Co (DIFC Empanel-registered, Regulator-Approved High-Privilege Panel member) and signed in December 2025 — presents a financial profile that is, by any measure, exceptional for a private pharmaceutical distributor.
| Financial Metric | FY2022-23 | FY2023-24 | FY2024-25 (Audited) | YoY Change |
| Net Revenue (USD Mn) | 1,880.5 | 2,268.6 | 3,035.4 | +33.8% |
| Gross Profit (USD Mn) | 141.8 | 168.9 | 270.5 | +60.2% |
| Gross Margin (%) | 7.5% | 7.4% | 8.9% | +150 bps |
| EBITDA (USD Mn) | ~89.0 | 106.3 | 198.6 | +86.9% |
| EBITDA Margin (%) | 4.7% | 4.7% | 6.5% | +185 bps |
| Net Profit to Shareholders (USD Mn) | 89.0 | 106.1 | 177.5 | +67.3% |
| Total Assets (USD Mn) | ~1,100* | 1,431.6 | 1,538.5 | +7.5% |
| Total Equity (USD Mn) | ~370* | 601.3 | 896.8 | +49.2% |
| Funded Debt (USD Mn) | Nil | 0.78 | 0.94 | Minimal |
| Cash & Equivalents (USD Mn) | ~46* | 67.4 | 160.3 | +138% |
| EPS (USD) | 1.19 | 1.42 | 2.37 | +0.95 |
* FY2022-23 balance sheet estimates sourced from 5-year trend data in FY2024-25 Annual Report. All other figures from FY2024-25 Audited Annual Report.
The headline figures tell a consistent story: five-year revenue CAGR of 22.7%, gross margin expanding 150 basis points to 8.9% in FY25, EBITDA nearly doubling year-on-year to USD 198.6 million, and total equity of USD 896.8 million against funded debt of just USD 0.94 million. The company’s Interest Coverage Ratio stands at 1,991 times — essentially limitless on current metrics. Even on a fully drawn USD 350 million revolving credit facility at a 7% all-in cost, that ratio would stand at approximately 8x — still well within investment-grade comfort parameters.
Critically, the company entered FY2025-26 with USD 160.3 million in cash — a 138% YoY increase — and no material funded borrowings. Its current ratio stands at 2.14x, comfortably above the 1.5x institutional benchmark for trading businesses.
| Balance Sheet Item | 30-Jun-2024 (USD Mn) | 30-Jun-2025 (USD Mn) | Commentary |
| Cash & Cash Equivalents | 67.4 | 160.3 | +138% — robust liquidity build |
| Trade Receivables | 1,004.4 | 1,009.3 | Stable; zero balances >180 days in FY25 |
| Inventories | 123.9 | 204.7 | +65%; new API safety stock + Perfume build |
| Total Assets | 1,431.6 | 1,538.5 | +7.5% YoY |
| Funded Debt | 0.78 | 0.94 | Effectively zero — debt-free enterprise |
| Trade Payables | 829.5 | 640.6 | Reduced by strategic early AP settlement |
| Total Equity | 601.3 | 896.8 | +49.2%; Nomas USD 175M injection reflected |
REVENUE ARCHITECTURE — FY2024-25 AUDITED
A Diversified USD 3 Billion Portfolio: Pharmaceuticals Lead, New Verticals Emerge
Beaufond’s USD 3.035 billion revenue base in FY2024-25 is not driven by a single product line or geography — a structural characteristic that distinguishes it from many single-segment trading peers. The Chemicals vertical, encompassing pharmaceutical APIs, fragrances, medical consumables, and industrial chemicals, remains the dominant contributor, supported by a fast-growing Other Merchandising segment that delivered a standout performance in FY25.
| Business Segment | FY2024-25 Revenue (USD Mn) | % of Total | FY2023-24 (USD Mn) | YoY Growth |
| Pharma Chemicals (APIs & Intermediates) | 1,589.6 | 52.4% | 1,349.0 | +17.8% |
| Perfumes & Fragrances | 296.9 | 9.8% | 137.3 | +116.3% |
| Medical Consumables | 186.3 | 6.1% | 143.7 | +29.6% |
| Other Basic Chemicals & Polymers | 76.3 | 2.5% | 63.7 | +19.8% |
| CHEMICALS VERTICAL TOTAL | 2,149.1 | 70.8% | 1,693.7* | +26.9% |
| Pharma Equipment & Machinery | 264.9 | 8.7% | 40.3 | +558.1% |
| Metals, Scrap & Minerals | 197.8 | 6.5% | 135.2 | +46.3% |
| Clothing & Textile | 116.9 | 3.9% | 99.2 | +17.8% |
| Agricultural Products & Other | 146.0 | 4.8% | 160.2* | — |
| OTHER MERCHANDISING TOTAL | 725.6 | 23.9% | 475.1* | +52.7% |
| Telecom Products (VoIP / Hardware) | 101.9 | 3.4% | 88.3 | +15.4% |
| Computer Software (Pharma Automation) | 58.6 | 1.9% | 27.5 | +113.1% |
| IT & TELECOM TOTAL | 160.8 | 5.3% | 140.5* | +14.4% |
| GROUP TOTAL | 3,035.4 | 100.0% | 2,268.6 | +33.8% |
* Segment sub-totals estimated from disclosed percentages and segment data in FY2024-25 Annual Report. Individual product line figures sourced directly from audited Annual Report Section 5.1.
Particularly noteworthy is the Pharma Equipment & Machinery sub-segment, which surged 558% to USD 264.9 million in FY25 — a line not widely modelled by pre-investment analyses. This vertical, focused on pre-owned pharmaceutical production equipment, protective gear, and compliance consumables, generated margins consistent with the broader Chemicals segment at approximately 8-9% at the gross level. This is a high-margin vertical with minimal incremental overhead, effectively riding Beaufond’s existing pharma customer relationships.
The Perfumes & Fragrances vertical more than doubled to USD 296.9 million — driven by volume growth with key clients across Malaysia, Bulgaria, and the United States — while the core Pharma Chemicals (APIs & Intermediates) business grew a steady 17.8% to USD 1.59 billion, forming the bedrock of Beaufond’s cash generation.
THE NOMAS CAPITAL BACKSTOP
USD 612 Million Abu Dhabi Commitment: What It Means for Beaufond’s European Push
In late 2024, Nomas Global Investments LLC-SPC — a Special Purpose Company wholly owned by H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan of the Abu Dhabi ruling family — committed USD 612 million to acquire a 70% strategic equity stake in Beaufond Plc. Of this commitment, USD 175 million has been deployed across two tranches (Tranche 1: USD 100 million; Tranche 2: USD 75 million). The remaining USD 437 million is earmarked specifically for the KIZAD (Khalifa Industrial Zone Abu Dhabi) greenfield pharmaceutical manufacturing facility, which is targeted for commissioning in FY2027-28.
The investment is purely financial — Nomas holds no board seats and has no management authority. According to documents reviewed by Network 7 Media Group, the Nomas Investment Committee awarded the investment a score of 4.4 out of 5 across seven institutional due diligence workstreams, with the financial quality workstream receiving the maximum score of 5/5.
It is important to note for readers that the Nomas investment does not imply a specific enterprise valuation of Beaufond. At current distribution-phase EBITDA multiples — which industry analysts typically place at 8-14x for API distributors — the implied enterprise value on FY25 EBITDA of USD 198.6 million would range from approximately USD 1.6 billion to USD 2.8 billion. The transformational value thesis for Nomas is predicated on post-KIZAD manufacturing multiples of 12-20x, which would materially re-rate the enterprise value at steady-state manufacturing EBITDA of USD 500 million or more — a scenario that remains contingent on KIZAD’s successful commissioning.
| Nomas Capital Deployment | Amount | Status | Purpose |
| Tranche 1 — Initial Injection | USD 100 Million | DEPLOYED (H2 FY25) | Equity injection; strategic AP settlement; WC strengthening |
| Tranche 2 — Balance Sheet | USD 75 Million | DEPLOYED (H2 FY25) | KIZAD Phase 1 capex; balance sheet strengthening |
| Tranches 3-5 — KIZAD | USD 437 Million | COMMITTED (FY26-28) | KIZAD greenfield manufacturing facility capex |
| TOTAL COMMITMENT | USD 612 Million | USD 175M Deployed | 70% equity stake in Beaufond Plc |
RECEIVABLES QUALITY & CREDIT PROFILE
A USD 1.009 Billion Receivables Book Running at 99.97% Recovery — and a Route to the USD 350 Million Facility
At the core of Beaufond’s financial credibility is its trade receivables portfolio: USD 1.009 billion as at 30 June 2025, carrying a verified historical recovery rate of 99.97% and zero receivables outstanding beyond 180 days in FY25 — a significant improvement from USD 42.8 million of long-dated receivables in FY2022-23. Days Sales Outstanding (DSO) declined from 142.6 days in FY24 to 120.9 days in FY25, reflecting genuine improvement in collection efficiency against a contractual maximum of 270 days.
The company’s top-tier customers include Pfizer (rated AA- by S&P), Sanofi-Aventis (A by Fitch), and Teva Pharmaceuticals (BB+ by S&P), all on five-to-seven-year rolling supply contracts. No single customer accounts for more than 10% of revenues — a diversification standard that compares favourably with API distribution peers, where the largest customer typically represents 15-25% of revenues.
Against this receivables base, Beaufond is seeking a USD 350 million revolving Working Capital Facility, with Bank of Africa (BOA) as the proposed lead arranger and Term Sheet in final sanction stages as of April 2026. The facility, structured as a self-liquidating revolving credit backed by trade receivables assignment, would carry a receivables coverage ratio of approximately 2.9 times at the FY25 base — well above the proposed covenant minimum of 2.0 times. The facility is explicitly ring-fenced from KIZAD capex by a negative covenant embedded in the term sheet.
| Key Credit & Receivables Metrics — FY2024-25 (Audited) |
| ► Historical receivables recovery rate: 99.97% (vs. 95-99% for API distribution peers) |
| ► Zero receivables outstanding beyond 180 days in FY25 (improved from USD 42.8M in FY23) |
| ► Days Sales Outstanding (DSO): 120.9 days (down from 142.6 days in FY24 — improving trend) |
| ► Trade receivables portfolio: USD 1,009.3 million (audited, Note 13, FY25 Annual Report) |
| ► Receivables coverage of proposed USD 350M facility: 2.88x (covenant minimum: 2.0x) |
| ► Zero LC / Bank Guarantee devolvement on record since inception |
| ► Zero payment defaults across all banking relationships (AECB: clean) |
| ► IVR AA / CRISIL AA investment-grade credit rating — best-in-class for private API distribution |
| ► Interest Coverage Ratio: 1,991x on current funded debt; ~8x if facility fully drawn at 7% |
KIZAD MANUFACTURING & IPO TRAJECTORY
From Distributor to Manufacturer: The KIZAD Transformation and the IPO Horizon
Beaufond’s European deal ambitions sit within a larger strategic framework: the transition from a value-added API distributor — with EBITDA margins of 6.5% at FY25 — to a fully integrated pharmaceutical manufacturer, targeting EBITDA margins of 18-25% at the Chemicals segment level post-KIZAD commissioning. This transformation is the central value creation thesis of the Nomas investment and the primary rationale for the FY2027-28 IPO target.
The KIZAD facility, to be sited within the Khalifa Economic Zones Abu Dhabi (KEZAD), is planned at 110,000 square metres of pharmaceutical production space, targeting 2.4 billion oral solid dosage units (tablets and capsules) per annum and 100 million sterile injectable units annually at full utilisation. Total capex is estimated at USD 1.0-1.15 billion, phased across FY2026-2028, funded by the Nomas USD 437 million remaining equity commitment plus an anticipated USD 700-850 million project finance syndicated term loan at the KIZAD SPV level.
As of April 2026, Phase 1 capex of USD 51.25 million has been incurred (reflected on Beaufond’s balance sheet as Plant & Machinery additions), funded entirely from the Nomas Tranche 2 injection. FEED (Front-End Engineering Design) commissioning is targeted for Q3-Q4 FY2026 — a critical-path milestone. KEZAD SPV incorporation, which must precede further KIZAD capex and project finance launch, is also outstanding as of the reporting date.
On the IPO side, Beaufond has initiated preparatory activities and is evaluating listing on Nasdaq Dubai, the London Stock Exchange Main Market, Euronext Amsterdam, and potentially the Saudi Tadawul. The company is transitioning its audit function to KPMG Lower Gulf Limited from FY2025-26 — three consecutive years of Big 4-audited accounts being the minimum standard for most major exchange listings. KPMG’s engagement letter is in final negotiation with execution targeted by 30 June 2026.
| KIZAD Milestone | Target Timeline | Status (April 2026) |
| Phase 1 Capex (Site Prep & Foundation) | Q4 FY2025-26 | USD 51.25M incurred — IN PROGRESS |
| KEZAD SPV Incorporation | Q1 FY2025-26 (revised: June 2026) | OUTSTANDING — Priority CP |
| FEED Commissioning | Q3-Q4 FY2025-26 | IN PROGRESS |
| EPC Contractor Selection | Q4 FY2025-26 (post-FEED) | Shortlist in progress |
| Phase 2 Construction (Buildings & Utilities) | Q1 FY2026-27 | COMMITTED — post-SPV |
| Phase 3 Equipment & Cleanrooms | Q4 FY2026-27 | COMMITTED |
| Phase 4 Validation & Regulatory | Q1 FY2027-28 | COMMITTED |
| Phase 5 Commissioning (First Commercial Batch) | Q4 FY2027-28 | TARGET |
| Project Finance Mandate (USD 700-850M) | Post-FEED (H1 FY2027) | PENDING FEED |
| IPO (Target Exchange — TBC) | FY2027-28 | Preparatory phase initiated |
STRATEGIC CONTEXT: WHAT THE DUTCH ALLIANCE WOULD MEAN
European Beachhead: Oncology and Anti-Malarial APIs as the Entry Point
Should the Netherlands supply agreement be concluded, it would represent Beaufond’s most significant European commercial engagement to date and the first formalisation of a continental EU manufacturing supply relationship. The oncology API market globally is estimated at USD 48 billion with a CAGR of approximately 8.5%, while the anti-malarial API segment — though smaller — remains structurally critical in bridging the supply chain between Asian manufacturers and European formulators serving global health markets.
Beaufond already has a London office (134 Buckingham Palace Road, SW1W 9SA) with regulatory liaison functions covering EMA and MHRA requirements, and its patent portfolio — 100 patents held by Discovery International Limited in Seychelles, carried at USD 80 million cost and independently valued at USD 124 million — includes five APIs launched in FY25 across oncology and cardiovascular indications with Drug Master File filings with the US FDA, EMA, and MHRA. The Dutch partnership would be a natural commercial extension of these regulatory footholds.
For potential lenders and the market more broadly, the Dutch deal — if executed — would also serve as an independent validation of Beaufond’s customer pipeline quality in a highly regulated European market, supplementing the existing Pfizer, Sanofi, and Teva relationships. It is worth noting, however, that Network 7 Media Group has not independently verified the identity of the Dutch pharmaceutical company, the quantum of the deal, or its contractual terms, which remain confidential pending finalisation.
| “Beaufond’s regulatory credentials — US FDA, EMA, MHRA, WHO-GMP, PIC/S, ISO 9001 — allow it to serve as a compliant supply partner in Europe’s most demanding pharmaceutical markets from day one. The Dutch negotiation is, in that sense, a logical consequence of a decade-long regulatory investment.” |
RISK FACTORS — INDEPENDENT ASSESSMENT
Balanced Perspective: What Could Temper the Growth Story
Network 7 Media Group’s independent assessment of Beaufond identifies several risk factors that investors, lenders, and counterparties should weigh alongside the company’s strong financial metrics:
KIZAD execution risk: The greenfield pharmaceutical facility remains the highest-rated risk in the company’s own COSO enterprise risk register, with a pre-mitigation score of 12 (HIGH). Construction delays, cost overruns, EPC contractor quality, and regulatory pre-approval timelines all represent material execution risks. The KEZAD SPV incorporation — a prerequisite for project finance launch — was originally targeted for Q1 FY2025-26 and remains outstanding as of April 2026.
Audit quality transition: FY2025 and prior years were audited by Youssry & Co, a DIFC Empanel-registered firm. While the firm holds Regulator-Approved High-Privilege Panel status and issued a clean, unqualified opinion on FY25, the transition to KPMG Lower Gulf Limited — targeted for FY2025-26 — is not yet formalised as of this report. Three consecutive years of Big 4 audit are required for most major stock exchange listings, making the KPMG engagement letter a time-critical item.
Trade credit insurance: Beaufond’s trade credit insurance is provided by a UAE-based domestic insurer. The reinsurance chain — which would typically indicate backing from an internationally rated reinsurer such as Munich Re, Swiss Re, Euler Hermes, or Atradius — has not been publicly confirmed. This is a point that institutional lenders and the BOA facility syndicate will probe during due diligence.
Key man insurance: As of April 2026, formal key man insurance policies on the CEO, CFO, COO, and Managing Director have not yet been arranged — an item flagged as outstanding since the Nomas pre-investment audit of November 2024.
Negative operating cash flow: FY2025 operating cash flow was negative USD 77.5 million, driven entirely by the strategic accelerated trade payable settlement of USD 188.6 million funded by the Nomas injection. Adjusted for this one-off item, underlying free cash flow was positive USD 111 million. The one-off nature has been verified, but lenders and analysts will scrutinise FY2026 operating cash flow closely for normalisation.
Board independence: As of April 2026, one of three board members (33%) is independent — below the 50% threshold targeted by the company for FY2026 and required by major listing exchanges. Two additional Independent Non-Executive Directors are planned for H2 FY2026 as a condition precedent to the next Nomas capital tranche.
FORWARD OUTLOOK
FY2025-26 Projections: A USD 3.5 Billion Base Case, With KIZAD Reshaping the Margin Profile
Based on the company’s historical 5-year revenue CAGR of 22.7%, moderated for base effects and the continued scaling of its Chemicals and Other Merchandising verticals, Beaufond’s own management projections indicate a base-case FY2025-26 revenue of approximately USD 3.55 billion, with EBITDA of USD 265 million at a 7.5% margin — representing further expansion from FY25’s 6.5%.
The transformational shift in the financial profile is not expected until FY2027-28, when KIZAD Phase 1 production commences at 40-50% utilisation. At that point, the blended group EBITDA margin is projected to begin its trajectory toward the 10-12% range (base case) on a revenue base of USD 5.0-6.0 billion, with the Chemicals segment alone targeting 18-25% EBITDA margins at the manufacturing level.
Whether the Dutch API supply agreement, when finalised, contributes meaningfully to FY2026 numbers will depend on contract commencement dates, credit terms, and ramp-up schedules — all of which remain confidential. What is verifiable is that any new European pharmaceutical supply contract of the scale being discussed would feed into the same trade receivables pool that already underpins Beaufond’s USD 350 million working capital facility application — a portfolio with a 99.97% historical recovery rate.
| Projection Metric | FY25 Actual | FY26 Base Case | FY27 Base Case | FY28 Base Case |
| Revenue (USD Mn) | 3,035 | 3,550 | 4,300 | 5,250 |
| EBITDA (USD Mn) | 199 | 265 | 360 | 525 |
| EBITDA Margin (%) | 6.5% | 7.5% | 8.4% | 10.0% |
| Net Profit — Shareholders (USD Mn) | 178 | 205 | 240 | 360 |
| Net Debt / EBITDA | Net Cash | ~0.4x | ~1.2x | ~0.8x |
| EPS (USD) | 2.37 | 2.73 | 3.20 | 4.80 |
Source: Beaufond Plc management projections (IM-2026-Apr-01). Base case assumes 20% revenue CAGR; KIZAD Phase 1 commissioning at 40-50% utilisation from FY27. These are forward-looking estimates, not audited figures.
COMPANY AT A GLANCE
| Parameter | Detail |
| Full Legal Name | Beaufond Plc |
| Incorporation Date | 15 April 2009 |
| Headquarters | Dubai International Financial Centre (DIFC), UAE — Reg. No. 3122 |
| Operating Countries | 50+ countries across 6 continents |
| Global Offices | 32 offices in 17 countries |
| Employees | 177 professionals globally (April 2026) |
| Primary Business Verticals | APIs & Specialty Chemicals | IT & Telecom | Diversified Merchandise |
| Credit Rating | IVR AA / CRISIL AA (Investment Grade — Annual Surveillance) |
| External Auditors (FY25) | Youssry & Co Auditing & Consultancy (DIFC High-Privilege Panel) |
| Transitioning to (FY26) | KPMG Lower Gulf Limited (Big 4 — engagement in final negotiation) |
| Major Shareholders | Nomas Global Investments LLC-SPC: 70% | Luxse Inc (25 HNIs): 30% |
| Revenue (FY2024-25, Audited) | USD 3,035.4 Million |
| EBITDA (FY2024-25, Audited) | USD 198.6 Million (6.5% margin) |
| Total Equity (30-Jun-2025) | USD 896.8 Million |
| Funded Debt | USD 0.94 Million (effectively zero) |
| Cash & Equivalents | USD 160.3 Million |
| Working Capital Facility (Proposed) | USD 350 Million Revolving — Bank of Africa (BOA) Lead Arranger |
| KIZAD Manufacturing (Planned) | 110,000 sqm | 2.4 Bn tablets/capsules p.a. | FY2027-28 commissioning |
| Target IPO | FY2027-28 — Exchange under evaluation |
| Key Regulatory Accreditations | US FDA | EMA | UK MHRA | Health Canada | TGA | WHO-GMP | PIC/S |
| Corporate Website | www.beaufond.com |
EDITORIAL NOTE
This report is independently researched and produced by Network 7 Media Group’s Global Business Desk. All financial figures are sourced from Beaufond Plc’s FY2024-25 Audited Annual Report (audited by Youssry & Co, DIFC; signed December 2025), publicly available information memoranda, and investment thesis documents reviewed by Network 7 Media Group. Forward projections are those of Beaufond Plc management and are presented as such — they are not guaranteed and involve material uncertainties. The identity of the Netherlands-based pharmaceutical counterparty in the reported negotiations has not been independently verified by Network 7 Media Group; we report the information as made available to us and note the discussions are ongoing and not yet formalised. This report does not constitute investment advice.
